NYSE:MRK News 2 December 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck & Co., Inc. (NYSE: MRK) heads into Monday’s U.S. session (December 15, 2025) with investors juggling a mix of near-term headlines and long-term franchise questions: a fresh dividend “reset” that makes Dec. 15 an important calendar day, ongoing scrutiny

14 December 2025

Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) ended Friday, December 12, 2025, at $100.30, climbing 1.30% on the day and finishing slightly higher for the week after a choppy stretch driven by vaccine-policy headlines and scrutiny around RSV preventive therapies. StockAnalysis

13 December 2025

Financial Updates · Investment News · Market Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock After Hours on Dec. 12, 2025: Winrevair EU Tailwind, Analyst Targets, and What to Watch Before the Next Open

Merck & Company, Inc. (NYSE: MRK) ended Friday, December 12, 2025, as a relative bright spot in a broadly weak session for U.S. equities. The stock closed at $100.30 (+1.30%), extending its winning streak to three straight days even as

13 December 2025

Earnings Analysis · Investment Strategies · Market News · NYSE:MRK · Pharma Stocks · Stock Market

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in

12 December 2025

Financial Forecasts · Investment Analysis · NYSE:MRK · Patent News · Pharmaceuticals · Stock Market

Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025

Merck & Co., Inc. (NYSE: MRK) heads into mid‑December with its stock back near the psychologically important $100 level—and with the kind of headline mix that makes long-term pharma investing feel like chess played on a trampoline: upbeat analyst upgrades

12 December 2025

Analyst Forecasts · Financial Updates · Investment Tips · Merck News · NYSE:MRK · Stock Market

Merck (MRK) Stock After Hours on December 10, 2025: What to Watch Before the December 11 Open

Merck & Co., Inc. (NYSE: MRK) heads into the December 11, 2025 U.S. trading session with its share price stabilizing after a volatile stretch driven by earnings, pipeline news, and a major flu-drug acquisition. Here’s a structured look at what

11 December 2025

After Hours Trading · Financial News · Investment Tips · Merck · NYSE:MRK · Stock Market

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. (NYSE: MRK) stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow

10 December 2025

Analyst Insights · Dividend Investing · Market Trends · NYSE:MRK · Pharmaceuticals · Stock Analysis

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda

10 December 2025

Financial Forecasts · Healthcare Industry · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the

10 December 2025

After-Hours Trading · Keytruda · Merck · NYSE:MRK · Pharmaceuticals · Stock Market

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a

8 December 2025

Company News · Financial Analysis · Investing · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt

7 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck & Co., Inc. (NYSE: MRK) is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life

2 December 2025

Dividends · FDA Approvals · NYSE:MRK · Pharmaceuticals · Stock Market · Wall Street Analysis

NYSE:MRK News 2 December 2025 - 14 December 2025